Literature DB >> 1716287

Protein kinase C plays a role in the induction of tyrosine phosphorylation of lymphoid microtubule-associated protein-2 kinase. Evidence for a CD3-associated cascade that includes pp56lck and that is defective in HPB-ALL.

A E Nel1, C Hanekom, L Hultin.   

Abstract

Ligation of the CD3 receptor induces multiple signal transduction events that modify the activation state of the T cell. We have compared two lines that express biologically active CD3 receptors but differ in their biochemical activation pathways during ligation of this receptor. Jurkat cells respond to anti-CD3 with Ca2+ mobilization, PKC activation, induction of protein tyrosine phosphorylation, and activation of newly characterized lymphoid microtubule associated protein-2 kinase (MAP-2K). MAP-2K itself is a 43-kDa phosphoprotein that requires tyrosine phosphorylation for activation. Although ligation of the CD3 receptor in HPB-ALL could stimulate tyrosine phosphorylation of a 59- kDa substrate, there was no associated induction of [Ca2+]i flux, PKC, or MAP-2K activation. A specific PKC agonist, PMA, which bypasses the CD3 receptor, could, however, activate MAP-2K in HPB-ALL cells. This implies that defective stimulation of PKC by the CD3 receptor is responsible for its failure to activate MAP-2K in HPB-ALL. The defect in PKC activation is likely distal to the CD3 receptor as A1F14- failed to activate MAP-2K in HPB-ALL but was effective in Jurkat cells. The stimulatory effect of PMA on MAP-2K activity in HPB-ALL was accompanied by tyrosine phosphorylation of this kinase which implies that PKC may, in some way, regulate tyrosine phosphorylation of MAP-2K. A candidate for this role is pp56lck which underwent posttranslational modification (seen as mobility change on SDS-PAGE) during anti-CD3 and PMA stimulation in Jurkat or PMA treatment in HPB-ALL. There was, in fact, exact coincidence between induction of PKC activity, posttranslational modification of lck and tyrosine phosphorylation/activation of MAP-2K. Lck kinase activity in an immune complex kinase assay was unchanged during PMA treatment. An alternative explanation is that modification of lck may alter its substrate profile. We therefore looked at the previously documented ability of PKC to dissociate lck from the CD4 receptor and found that PMA could reduce the stoichiometry of the lck interaction with CD4 in HPB-ALL and to a lesser extent in Jurkat cells. These results imply the existence of a kinase cascade that is initiated by PKC and, in the course of which, lck and MAP-2K may interact.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716287

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Mitogen-activated protein kinase (MAPK) in cardiac tissues.

Authors:  C Page; A F Doubell
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

2.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

3.  Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes.

Authors:  R A Franklin; A Tordai; H Patel; A M Gardner; G L Johnson; E W Gelfand
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

4.  Patterns of HIV-1 protein interaction identify perturbed host-cellular subsystems.

Authors:  Jamie I MacPherson; Jonathan E Dickerson; John W Pinney; David L Robertson
Journal:  PLoS Comput Biol       Date:  2010-07-29       Impact factor: 4.475

5.  Protein phosphorylation in murine peritoneal macrophages induced by infection with Salmonella species.

Authors:  S Saito; H Shinomiya; M Nakano
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line.

Authors:  G Kumar; S Wang; S Gupta; A Nel
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

7.  Okadaic acid activates p42 mitogen-activated protein kinase (MAP kinase; ERK-2) in B-lymphocytes but inhibits rather than augments cellular proliferation: contrast with phorbol 12-myristate 13-acetate.

Authors:  A M Casillas; K Amaral; S Chegini-Farahani; A E Nel
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

8.  Activation of mitogen-activated protein kinase/ERK-2 in phytohaemagglutin in blasts by recombinant interleukin-2: contrasting features with CD3 activation.

Authors:  R M Fairhurst; M Daeipour; M C Amaral; A E Nel
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

9.  Contrasting effects of two tumour promoters, phorbol myristate acetate and okadaic acid, on T-cell responses and activation of p42 MAP-kinase/ERK-2.

Authors:  M C Amaral; A M Casillas; A E Nel
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

Review 10.  Signal transduction pathways involving the Raf proto-oncogene.

Authors:  N G Williams; T M Roberts
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.